Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT04433858

An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)

Status
Active Not Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
27 (actual)
Sponsor
Sheppard Pratt Health System · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The primary objective of this study is to evaluate the efficacy of psilocybin (25 mg) administered under supportive conditions to adult participants with severe TRD, in improving depressive symptoms.

Conditions

Interventions

TypeNameDescription
DRUGPsilocybinopen-label

Timeline

Start date
2021-03-01
Primary completion
2025-06-01
Completion
2026-05-01
First posted
2020-06-16
Last updated
2024-08-09

Locations

2 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT04433858. Inclusion in this directory is not an endorsement.